Early research (Phase 1)UnknownNCT00431808What this trial is testingSafety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545])Who this might be right forMalaria African Malaria Network Trust 40
Testing effectiveness (Phase 2)Study completedNCT03203421What this trial is testingA Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2Who this might be right forMalaria University of Oxford 18
Early research (Phase 1)Study completedNCT00374998What this trial is testingSafety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PPWho this might be right forMalaria, FalciparumMalaria European Vaccine Initiative 35
Early research (Phase 1)Study completedNCT00513669What this trial is testingPhase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in TanzaniaWho this might be right forFalciparum Malaria Swiss Tropical & Public Health Institute 50
Early research (Phase 1)Study completedNCT01988636What this trial is testingStudy of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African AdultsWho this might be right forMalaria National Institute of Allergy and Infectious Diseases (NIAID) 296
Large-scale testing (Phase 3)Study completedNCT02699099What this trial is testingImmunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.Who this might be right forMalariaMalaria Vaccines GlaxoSmithKline 699
Early research (Phase 1)Study completedNCT02942277What this trial is testingSafety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in MaliWho this might be right forMalaria National Institute of Allergy and Infectious Diseases (NIAID) 301
Testing effectiveness (Phase 2)Study completedNCT03824236What this trial is testingEvaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve AdultsWho this might be right forMalaria GlaxoSmithKline 61
Early research (Phase 1)Not Yet RecruitingNCT07831226What this trial is testingSafety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-59 YearsWho this might be right forMalaria Vaccine Guangzhou Patronus Biotech Co., Ltd. 72
Not applicableStudy completedNCT00766662What this trial is testingIntermittent Preventive Treatment in Infant in MaliWho this might be right forMalaria University of Bamako
Testing effectiveness (Phase 2)Study completedNCT02044198What this trial is testingA Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum MalariaWho this might be right forPlasmodium Falciparum Malaria University of Oxford 30
Testing effectiveness (Phase 2)Study completedNCT00360230What this trial is testingPartially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian ChildrenWho this might be right forMalaria GlaxoSmithKline 540
Not applicableStudy completedNCT07194499What this trial is testingKnowledge and Attitude Among Healthcare Workers Towards Malaria Vaccine, Sudan 2025.Who this might be right forMalariaMalaria Vaccine Research and Publication office 222
Large-scale testing (Phase 3)Study completedNCT04319380What this trial is testingSeasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension StudyWho this might be right forMalaria,FalciparumChild, Only London School of Hygiene and Tropical Medicine 5,098
Not applicableStudy completedNCT06450379What this trial is testingImpact of Vaccines on Antimicrobial Microbial ResistanceWho this might be right forVaccine Malawi Liverpool Wellcome Programme 13,200
Testing effectiveness (Phase 2)Study completedNCT02925403What this trial is testingAssess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 AdjuvantWho this might be right forMalaria University of Oxford 13
Testing effectiveness (Phase 2)Study completedNCT01658696What this trial is testingEfficacy of Candidate Malaria Vaccines in Senegalese AdultsWho this might be right forMalaria University of Oxford 120
Testing effectiveness (Phase 2)Study completedNCT01031524What this trial is testingTrial to Assess the Efficacy of Malaria Vaccine PfCS 102Who this might be right forPlasmodium Falciparum Malaria Swiss Tropical & Public Health Institute 16
Early research (Phase 1)Study completedNCT06461026What this trial is testingL9LS MAb in Malian InfantsWho this might be right forMalaria National Institute of Allergy and Infectious Diseases (NIAID) 327
Early research (Phase 1)Study completedNCT03084289What this trial is testingAssess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of AdministrationWho this might be right forMalaria University of Oxford 26